ESC 365 - Stroke rate after twelve versus 30 month dual antiplatelet therapy in percutaneous coronary intervention patients using korean national health insurance service (nhis)

ESC Premium Access

Stroke rate after twelve versus 30 month dual antiplatelet therapy in percutaneous coronary intervention patients using korean national health insurance service (nhis)

Session: Remaining in the spotlight: antiplatelet agents

Topic: Drug therapy

Speaker: Miss S. Kang (Busan, KR)

Event: ESC Congress 2017

Congress Presentation

Add to my library

About the speaker

Miss Sayul Kang

Busan (Korea (Republic of))

0 follower

6 more presentations in this session

Temporal trends in the use of antiplatelet therapy in patients with acute coronary syndromes

Speaker: Doctor M. Esteve Pastor (Murcia, ES)

The effect of CYP2C19 gene polymorphism on clinical outcomes in patients with CAD receiving antiplatelet therapy.

Speaker: Mr W. Liu (Beijing, CN)

Efficacy and safety of perioperative aspirin therapy in non-cardiac surgery: a systematic review and comprehensive meta-analysis of randomized controlled trials

Speaker: Mr G. Wolff (Ibbenbüren, DE)

Antiplatelet therapy and adverse outcomes in high cardiovascular risk elderly patients: a sex and gender focused analysis from REPOSI study

Speaker: Doctor M. Proietti (Milan, IT)

Anti-platelet effect of intravenous P2Y12 receptor inhibitor cangrelor is not influenced by reticulated platelets

Speaker: Doctor C. Stratz (Bad Krozingen, DE)

Access the full session

Remaining in the spotlight: antiplatelet agents

Speakers: Miss S. Kang, Doctor M. Esteve Pastor, Mr W. Liu, Mr G. Wolff, Doctor M. Proietti...

About the event

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources